Zacks: Analysts Expect ChromaDex Co. (NASDAQ:CDXC) to Announce -$0.09 EPS

Brokerages expect that ChromaDex Co. (NASDAQ:CDXCGet Rating) will report earnings of ($0.09) per share for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for ChromaDex’s earnings, with the highest EPS estimate coming in at ($0.07) and the lowest estimate coming in at ($0.12). ChromaDex posted earnings per share of ($0.12) in the same quarter last year, which suggests a positive year-over-year growth rate of 25%. The company is scheduled to report its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that ChromaDex will report full year earnings of ($0.26) per share for the current year, with EPS estimates ranging from ($0.40) to ($0.12). For the next year, analysts expect that the firm will report earnings of ($0.15) per share, with EPS estimates ranging from ($0.34) to ($0.06). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for ChromaDex.

ChromaDex (NASDAQ:CDXCGet Rating) last posted its quarterly earnings data on Wednesday, March 9th. The company reported ($0.08) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.11) by $0.03. The firm had revenue of $17.76 million during the quarter, compared to analysts’ expectations of $18.42 million. ChromaDex had a negative net margin of 40.22% and a negative return on equity of 70.85%. During the same quarter last year, the company posted ($0.10) EPS.

Several equities analysts have commented on the stock. Zacks Investment Research raised shares of ChromaDex from a “sell” rating to a “hold” rating in a research report on Tuesday. Roth Capital assumed coverage on shares of ChromaDex in a research report on Tuesday, March 8th. They issued a “buy” rating and a $7.00 price target for the company. HC Wainwright decreased their price target on shares of ChromaDex from $12.00 to $8.00 and set a “buy” rating for the company in a research report on Monday. StockNews.com assumed coverage on shares of ChromaDex in a research report on Thursday, March 31st. They issued a “hold” rating for the company. Finally, B. Riley decreased their price target on shares of ChromaDex from $16.00 to $8.00 and set a “buy” rating for the company in a research report on Thursday, March 10th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, ChromaDex currently has an average rating of “Buy” and an average target price of $7.56.

Shares of NASDAQ:CDXC traded down $0.03 during mid-day trading on Friday, reaching $1.96. 8,243 shares of the company were exchanged, compared to its average volume of 473,192. ChromaDex has a 1 year low of $1.93 and a 1 year high of $10.78. The firm has a market cap of $133.89 million, a price-to-earnings ratio of -4.78 and a beta of 1.72. The firm’s 50-day simple moving average is $2.47 and its 200 day simple moving average is $3.85.

In related news, CEO Robert N. Fried purchased 25,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 16th. The shares were purchased at an average cost of $2.16 per share, for a total transaction of $54,000.00. The purchase was disclosed in a document filed with the SEC, which is available through this link. 11.84% of the stock is owned by company insiders.

A number of large investors have recently made changes to their positions in CDXC. BlackRock Inc. increased its stake in ChromaDex by 1.6% in the fourth quarter. BlackRock Inc. now owns 3,195,064 shares of the company’s stock valued at $11,950,000 after purchasing an additional 51,383 shares during the period. Barclays PLC increased its stake in ChromaDex by 18.2% in the third quarter. Barclays PLC now owns 956,741 shares of the company’s stock valued at $5,999,000 after purchasing an additional 147,437 shares during the period. State Street Corp increased its stake in ChromaDex by 1.2% in the fourth quarter. State Street Corp now owns 896,218 shares of the company’s stock valued at $3,352,000 after purchasing an additional 10,855 shares during the period. Geode Capital Management LLC increased its stake in ChromaDex by 2.0% in the fourth quarter. Geode Capital Management LLC now owns 881,268 shares of the company’s stock valued at $3,295,000 after purchasing an additional 17,054 shares during the period. Finally, Uniplan Investment Counsel Inc. increased its stake in ChromaDex by 0.3% in the third quarter. Uniplan Investment Counsel Inc. now owns 681,002 shares of the company’s stock valued at $4,269,000 after purchasing an additional 1,737 shares during the period. Hedge funds and other institutional investors own 40.02% of the company’s stock.

About ChromaDex (Get Rating)

ChromaDex Corporation operates as a bioscience company focusing on healthy aging. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches on nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers, as well as to distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.

Further Reading

Get a free copy of the Zacks research report on ChromaDex (CDXC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for ChromaDex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChromaDex and related companies with MarketBeat.com's FREE daily email newsletter.